From Model To Molecule: Combining AI And Experimental Strategies To Transform Drug Development

Artificial intelligence–driven predictive modeling is transforming many aspects of drug development, enabling faster insights and more informed decision-making. However, computational approaches still require experimental validation to confirm their accuracy and reliability, and they may not be suitable for every application. To ensure continued progress, a carefully planned and well-executed experimental strategy remains essential. This is particularly critical when evaluating the solid-state properties of active pharmaceutical ingredients (APIs), which play a fundamental role in rational drug product development.

In our recent webinar, experts shared real-world case studies demonstrating how integrating computational modeling with experimental approaches can help overcome methodological limitations, strengthen confidence in results, and support more effective development decisions. Key themes included addressing situations where computational methods may be unavailable or unreliable, combining predictive modeling with experimental validation to achieve accurate outcomes, and highlighting important considerations when assessing the solid-state properties of APIs during drug development.